Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Skin Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL17C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL17C ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL17C Products |
| Gene Delivery | IL17C Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL17C Products |
| Benchmark Ab | Anti-IL17C (Sequence of Deleobart) Recombinant positive control. |
View IL17C Products |
| Validator | IL17C siRNA Set For knockdown verification. |
View IL17C Products |
| Related Target A | IL17RE Specific functional receptor for IL17C signaling pathway activation. |
View IL17RE Products |
| Related Target B | IL17RA Shared receptor subunit essential for IL17C-induced signal transduction. |
View IL17RA Products |
| Related Target C | IL17A Key cytokine for selectivity and cross-reactivity profiling. |
View IL17A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human, Mouse, and Cynomolgus ortholog IL17C proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (IL17A to IL17F) strictly verified by SDS-PAGE and Mass Spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL17C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL17C therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to localized epithelial barrier modulation. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific modalities and tissue-specific delivery mechanisms.
IL17C is an epithelial cell-derived cytokine that plays a distinct role in skin and mucosal immunity by binding to the IL17RE/IL17RA receptor complex. Unlike IL17A, which is primarily produced by T-cells, IL17C acts in an autocrine/paracrine loop on epithelial cells, driving the expression of proinflammatory cytokines and antimicrobial peptides. Blocking this pathway offers a highly localized therapeutic strategy for inflammatory skin diseases like atopic dermatitis and psoriasis, minimizing systemic safety concerns.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | LEO Pharma, MorphoSys, Galapagos | Atopic Dermatitis, Psoriasis | Receptor Blocking Assay (Need high-purity homodimeric IL17C and IL17RE) |
| Bispecific Antibody | Innovative Biotechs | Chronic Inflammatory Diseases | Dual-Target Binding Verification (Need cross-reactive IL17C and IL17A/F proteins) |
| Small Molecule / Peptide | Early-stage Discovery | Autoimmune Disorders | HTS Screening & Cell-based Assays (Need stable IL17RE-expressing cell lines via Lentivirus) |